Penserra Capital Management LLC increased its position in shares of Petmed Express Inc (NASDAQ:PETS) by 172.7% during the 4th quarter, Holdings Channel reports. The firm owned 327,359 shares of the company’s stock after purchasing an additional 207,331 shares during the quarter. Petmed Express makes up approximately 2.0% of Penserra Capital Management LLC’s holdings, making the stock its 10th largest holding. Penserra Capital Management LLC’s holdings in Petmed Express were worth $14,894,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Verity Asset Management Inc. purchased a new position in Petmed Express during the fourth quarter worth about $274,000. LS Investment Advisors LLC boosted its holdings in Petmed Express by 283.5% during the fourth quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock worth $130,000 after purchasing an additional 2,115 shares during the last quarter. CenterStar Asset Management LLC purchased a new position in Petmed Express during the fourth quarter worth about $169,000. Teacher Retirement System of Texas purchased a new position in Petmed Express during the fourth quarter worth about $327,000. Finally, Crossmark Global Holdings Inc. purchased a new position in Petmed Express during the fourth quarter worth about $337,000. Institutional investors and hedge funds own 96.66% of the company’s stock.

Several research analysts recently weighed in on PETS shares. Noble Financial restated a “hold” rating on shares of Petmed Express in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Petmed Express from a “sell” rating to a “hold” rating and set a $50.00 price target on the stock in a report on Friday, October 20th. BidaskClub cut shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Northcoast Research set a $58.00 price target on shares of Petmed Express and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $42.80.

Shares of Petmed Express Inc (NASDAQ PETS) opened at $42.87 on Monday. The company has a market cap of $883.17, a PE ratio of 25.37, a price-to-earnings-growth ratio of 2.52 and a beta of 0.95. Petmed Express Inc has a 12-month low of $19.21 and a 12-month high of $57.80.

Petmed Express (NASDAQ:PETS) last announced its quarterly earnings data on Monday, January 22nd. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.33 by $0.11. The business had revenue of $60.10 million for the quarter, compared to analyst estimates of $56.76 million. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 earnings per share. equities analysts predict that Petmed Express Inc will post 1.7 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Shareholders of record on Monday, February 5th will be given a $0.25 dividend. This is a positive change from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date is Friday, February 2nd. This represents a $1.00 annualized dividend and a yield of 2.33%. Petmed Express’s payout ratio is currently 59.17%.

In other Petmed Express news, Director Ronald J. Korn sold 5,000 shares of Petmed Express stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $48.38, for a total value of $241,900.00. Following the sale, the director now owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gian Fulgoni sold 20,000 shares of Petmed Express stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the completion of the sale, the director now directly owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,000 shares of company stock worth $3,229,500. Insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://theolympiareport.com/2018/02/12/petmed-express-inc-pets-stake-lifted-by-penserra-capital-management-llc.html.

Petmed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.